Omnicell (NASDAQ:OMCL) Upgraded at StockNews.com

Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Friday.

OMCL has been the subject of several other research reports. Bank of America decreased their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. JPMorgan Chase & Co. lowered their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Benchmark reissued a "buy" rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company lowered their price target on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $50.67.

Omnicell Trading Down 0.4 %

Shares of NASDAQ OMCL traded down $0.12 during midday trading on Friday, hitting $30.84. The stock had a trading volume of 333,385 shares, compared to its average volume of 536,254. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.75. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 114.23, a PEG ratio of 7.53 and a beta of 0.78. The company has a fifty day moving average price of $34.32 and a 200 day moving average price of $40.84.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Institutional Trading of Omnicell

Hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its holdings in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in Omnicell by 6.9% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock worth $213,000 after purchasing an additional 307 shares in the last quarter. Van ECK Associates Corp increased its holdings in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. raised its stake in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares in the last quarter. Finally, Redmond Asset Management LLC lifted its holdings in Omnicell by 0.3% during the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock worth $5,396,000 after buying an additional 371 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.